Graves Ophthalmopathy
Conditions
Brief summary
Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast proliferation and release of glycosaminoglycans. The current treatments available, especially glucocorticoids, are not effective in all patients. Two cases of patients with GO treated with Sirolimus have been reported with an excellent response to the drug. The rationale for the use of Sirolimus lies in its mechanisms of action. Sirolimus is able to inhibit T-cell activation as well as fibroblast proliferation. In addition, acts indirectly on the Insulin-Like Growth Factor-1 (IGF-1) pathway, and recent clinical trials have shown that a monoclonal antibody against the IGF-1 receptor (Teprotumumab) is effective in patients with GO. Thus, Sirolimus could be used in GO as monotherapy in patients with GO. The aim of the present drug vs standard treatment, observational study is to evaluate the efficacy of Sirolimus as a second-line treatment in patients with moderately severe, active GO.
Detailed description
Study Design: observational Thirty consecutive patients with moderate-to-severe and active GO treated with sirolimus (15 patients) or methylprednisolone (15 patients) observance 18 consecutive months will be compared. Study Timeline Baseline visit - (Time 0) Treatment period (week 1-week 12): daily administration of the trial agent (Sirolimus) or weekly administration of the standard treatment (methylprednisolone) Outcome visit (week 24)
Interventions
DRUGSirolimus
2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
DRUGMethylprednisolone
500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
Sponsors
University of Pisa
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients willing and capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form 2. A moderate-to-severe GO, defined as the presence of at least one of the following criteria: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm 3. Active GO: CAS (4) ≥2 out of 7 points in the most affected eye 4. Previous GO treatment with glucocorticoids and/or orbital radiotherapy and/or orbital decompressive surgery, performed more than 24 weeks before the current treatment 5. Male and female patients of age: 18-75 years
Exclusion criteria
1. Optic neuropathy 2. Treatment with glucocorticoids or other immunosuppressive medications, and/or selenium, and/or orbital radiotherapy and/or orbital decompressive surgery in the 24 weeks preceding the current treatment 3. Mental illness that prevents patients from comprehensive, written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GO overall response | 24 weeks | Percentage of subjects with at least two of the following compared to baseline: a) Improvement in clinical activity score (CAS) by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions ≥8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the clinical activity score (CAS) | 24 weeks | Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye |
| Change in quality of life | 24 weeks | Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL) |
| Change in exophthalmos | 24 weeks | Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye |
| Change in eyelid aperture | 24 weeks | Percentage of subjects with a reduction greater than or equal to 2 mm |
| Change in diplopia | 24 weeks | Percentage with an improvement in diplopia |
| Change in eye ductions | 24 weeks | Percentage of subjects with an increase in eye ductions at least 8 degrees |
Countries
Italy
Outcome results
None listed